A5054837722- Diabetes and associated disorders
- Pancreatic function and diabetes
- Diabetes Management and Research
- Diabetes Treatment and Management
- Heart Rate Variability and Autonomic Control
- Mental Health Research Topics
- Genetics and Neurodevelopmental Disorders
- Pancreatitis Pathology and Treatment
Mayo Clinic
2024-2025
Mater Misericordiae University Hospital
2010-2015
Abstract Aims HNF1A gene mutations are the most common cause of maturity‐onset diabetes young ( MODY ) in UK . Persons with HNF 1A– display sensitivity to sulphonylurea therapy; however, long‐term efficacy is not established. There limited literature as prevalence micro‐ and macrovascular complications this unique cohort. The aim study was determine natural progression clinical management a dedicated clinic. Methods Sixty patients cohort 60 BMI ‐, age‐, ethnicity‐ duration‐matched Type 1...
Abstract Type 1 diabetes (T1D) is a chronic condition characterized by glucose fluctuations. Laboratory studies suggest that cognition reduced when very low (hypoglycemia) and high (hyperglycemia). Until recently, technological limitations prevented researchers from understanding how naturally-occurring fluctuations impact cognitive This study leveraged advances in continuous monitoring (CGM) ecological momentary assessment (EMA) to characterize dynamic, within-person associations between...
The Automated Insulin Delivery in Elderly with Type 1 Diabetes (AIDE T1D) trial randomized 82 adults ≥65 years type diabetes (T1D) to hybrid closed loop (HCL), predictive low glucose suspend (PLGS), and sensor-augmented pump (SAP) therapy a crossover trial. Seventy-five of the 78 completers joined an extension phase which they were offered mode their choice for additional 3 months. Mean age was 71 ± 4 (range 65-86 years) mean duration T1D 42 17 1-68 years). Use HCL selected by 91%, PLGS 8%,...
Background: Inhaled technosphere insulin (TI, Afrezza®) has a more rapid onset of action than rapid-acting analogs (RAA). Methods: Forty-nine adults with type 1 diabetes (T1D) initiated regimen TI plus degludec for 13 weeks after completing 17 in the usual-care control group randomized trial. The initial dose, based on bioequivalence, was approximately two times RAA dose being used. primary outcome noninferiority daytime time-in-range (TIR) 70-180 mg/dL at weeks. Results: During preceding...
Background: Glycemic control has been studied in hospitalized patients with type 1 diabetes (T1D) or 2 (T2D) and more recently 3C who had total pancreatectomy (TP) islet autotransplantation (IAT). To our knowledge, we report the first study using continuous glucose monitoring (CGM) to assess TP without IAT during hospitalization. Methods: We completed blinded CGM (Dexcom G6 PRO) studies 27 subjects a nonintensive care unit setting at Mayo Clinic, Rochester, compared two cohorts (CGM data <...
Mutations in the transcription factor hepatocyte nuclear factor-1-alpha (HNF1A) result commonest type of maturity onset diabetes young (MODY). HNF1A-MODY carriers have reduced pancreatic beta cell mass, partially due to an increased rate apoptosis. To date, it has not been possible determine when apoptosis is occurring HNF1A-MODY.We recently demonstrated that stimulates expression stone protein/regenerating (PSP/reg) gene surviving neighbour cells, and PSP/reg1A protein subsequently secreted...
OBJECTIVE In diabetes, β-cell mass is not static but in a constant process of cell death and renewal. Inactivating mutations transcription factor 1 (tcf-1)/hepatocyte nuclear factor1a (hnf1a) result decreased HNF1A–maturity onset diabetes the young (HNF1A-MODY). Here, we investigated effect dominant-negative HNF1A mutant (DN-HNF1A) induced apoptosis on regenerative capacity INS-1 cells. RESEARCH DESIGN AND METHODS DN-HNF1A was expressed cells using reverse tetracycline-dependent...